ALNY vs IMDX · P/E 76, rev $1.29B vs rev $271.0K
Alnylam Pharmaceuticals Inc (ALNY) versus Insight Molecular Diagnostics Inc. (IMDX) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Insight Molecular Diagnostics Inc. (IMDX) is a diagnostics & research company listed on US.
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported IMDX revenue for 2026-06-30 was $271.0K. Net income was -$15.6M. IMDX currently screens at market cap $0.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. IMDX currently screens at market cap $0.
Not investment advice. Open the ALNY and IMDX stock pages for the full models.
Not investment advice.